Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advances in molecular profiling have uncovered significant heterogeneity among medulloblastomas and led to the identification of four distinct subgroups (wingless [WNT], sonic hedgehog [SHH], group 3, and group 4) that represent distinct disease entities in both underlying biology and clinical characteristics.
|
31574483 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In several of these cases, activation of HH-GLI signaling is mediated by overproduction of HH ligands (e.g., prostate cancer), loss-of-function mutations in <i>PTCH1</i> or gain-of-function mutations in <i>SMO</i>, which occur in the majority of basal cell carcinoma (BCC), SHH-subtype medulloblastoma and rhabdomyosarcoma.
|
31244888 |
2019 |
Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Herein, we review the main clinical and molecular features of the four consensus subgroups of MB (WNT, SHH, Group 3 and Group 4).
|
31799776 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent advances in molecular technologies allowed to classify MB in 4 major molecular subgroups: WNT, SHH, Group 3 and Group 4.
|
31346954 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Differential Expression of Mitochondrial Biogenesis Markers in Mouse and Human SHH-Subtype Medulloblastoma.
|
30841515 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inhibition of LDHA significantly reduced growth of both mouse and human <i>MYC</i>-driven tumors but had little effect on normal cerebellar cells or SHH-associated medulloblastoma.
|
30862721 |
2019 |
Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
About 30% of patients experience relapse after treatment, possibly because of our inability to identify and eliminate the cancer stem cells.Zhang et al. recently investigated these cells in the SHH subgroup of medulloblastoma and identified drugs that may target them.
|
31813451 |
2019 |
Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Principles of tumorigenesis and emerging molecular drivers of SHH-activated medulloblastomas.
|
31139698 |
2019 |
Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recent molecular analyses of pediatric and adult MB have classified these tumors into at least four individual molecular subgroups (SHH, WNT, group 3, and group 4) with distinct demographics, histology, and prognosis.
|
31236711 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, there were no reports investigating the relationships between preoperative hematological markers and the prognosis of medulloblastoma (MB) patients based on the molecular subgroups (WNT, SHH, Group 3, and Group 4).
|
31519974 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The majority of young children with SHH-subgroup medulloblastoma can be treated effectively with irradiation-sparing regimens.
|
31621042 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein we report two adolescent patients with Group 4 and SHH medulloblastoma, where vinblastine successfully replaced vincristine with resolution of their peripheral neuropathy.
|
30848061 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is a pediatric malignant brain tumor composed of four different subgroups (WNT, SHH, Group 3, Group 4), each of which are a unique biological entity with distinct clinico-pathological, molecular, and prognostic characteristics.
|
30890619 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is the most frequent malignant brain tumor in children and it is subgrouped into 4 entities (SHH, WNT, Group 3, and Group 4).
|
31073205 |
2019 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To characterize medulloblastoma at the phosphoprotein-signaling level, we performed high-throughput peptide phosphorylation profiling on a large cohort of SHH (Sonic Hedgehog), group 3, and group 4 medulloblastomas.
|
29562177 |
2018 |
Medulloblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A Kaplan-Meier survival curve and multivariate Cox regression demonstrated that high M1 expressers showed worse overall survival (OS) and progression-free survival (PFS) than low M1 expressers in SHH MB, with relative risk (RR) values of 11.918 and 6.022, respectively.
|
29739450 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medulloblastoma (MB) is an embryonal tumour that originates from genetic deregulation of cerebellar developmental pathways and is classified into 4 molecular subgroups: SHH, WNT, group 3, and group 4.
|
29582271 |
2018 |
Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Targeting of oncogene-driven replicative stress as therapeutic option for high-risk medullobastoma was assessed using a panel of medulloblastoma cells differing in their c-Myc expression [i.e. group SHH (c-Myc low) vs. group 3 (c-Myc high)].
|
29753759 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MB tumors belonging to SHH molecular subgroup, with TP53<sup>MUT</sup>, would be the ones that present high risk in relation to VA use during the treatment, while TP53<sup>WT</sup> MBs can benefit from VA therapy, both SHH and groups 3 and 4.
|
29785653 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Biomarkers were identified applying stringent selection filters and Linear Discriminant Analysis (LDA) method, and validated using DNA methylation microarray data, bisulfite pyrosequencing, and direct-bisulfite sequencing.<b>Results:</b> Using a LDA-based approach, we developed and validated a prediction method (<sup>Epi</sup>WNT-SHH classifier) based on six epigenetic biomarkers that allowed for rapid classification of medulloblastoma into the clinically relevant subgroups WNT, SHH, and non-WNT/non-SHH with excellent concordance (>99%) with current gold-standard methods, DNA methylation microarray, and gene signature profiling analysis.
|
29351917 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides novel candidates whose functional role should be further investigated in SHH MB.
|
30096798 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specifically, SHH medulloblastomas displayed strong signatures of fibroblasts, T cells and macrophages, while markers of cytotoxic lymphocytes were enriched in Group 4 tumors.
|
30228931 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have implemented several biochemical experiments using human MB tumor microarray (TMA) and pediatric MB cell lines, derived from high-risk SHH-TP53-mutated and MYC-amplified Non-WNT/SHH tumors.
|
29280516 |
2018 |
Medulloblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
TP53-wildtype SHH-activated MDB is more commonly of desmoplastic/nodular morphology, and can be related to PTCH1 deletion and 10q loss.
|
29582169 |
2018 |
Medulloblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prognostic biomarkers and models identified were validated in an independent, demographically matched cohort (n=70) of medulloblastoma patients with non-WNT/non-SHH standard-risk disease treated with conventional therapies (maximal surgical resection followed by adjuvant craniospinal irradiation [all patients] and chemotherapy [65 of 70 patients], at UK Children's Cancer and Leukaemia Group and European Society for Paediatric Oncology (SIOPE) associated treatment centres between 1990 and 2014.
|
30392813 |
2018 |